Common Contracts
30 similar License Agreement contracts
License AgreementLicense Agreement • July 1st, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of01/07/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Syngene International Limited a company registered under the laws of India , and having as principal place of business at
License AgreementLicense Agreement • March 18th, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of18/03/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and PHARMACEUTICAL FIRM “DARNITSA”, a company registered under the laws of Ukraine, and having as principal place of business at 13, Boryspilska str., 02093 Kyiv (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • March 8th, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 10/03/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Cipla Limited, a company registered under the laws of India and having as principal place of business at Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013 (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • March 7th, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of07/03/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Beximco Pharmaceuticals Limited a company registered under the laws of the People’s Republic of Bangladesh and having as principal place of business at 17, Dhanmondi R/A, Road No. 2, Dhaka, Bangladesh and Operational Headquarters at 19, Dhanmondi R/A, Road # 7, Dhaka 1205, Bangladesh (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • March 4th, 2022 • New York
WHEREAS, in accordance with Pfizer-MPP Agreement (as hereinafter defined), MPP has been granted by PF PRISM Holdings B.V., a private limited company (besloten vennootschap) having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“Pfizer”), the right to sublicense certain Patents (as hereinafter defined) and Licensed Know-How (as hereinafter defined) regarding (a) the Compound (as hereinafter defined) used in Product (as hereinafter defined) and Licensed Product (as hereinafter defined), (b) the Product and (c) the Licensed Product, in furtherance of its policy of improving access to COVID-19 medicines in the Territory (as hereinafter defined);
LICENSE AGREEMENTLicense Agreement • March 4th, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Mylan Laboratories Limited a company registered under the laws of
R E C I T A L SLicense Agreement • March 3rd, 2022 • New York
WHEREAS, in accordance with Pfizer-MPP Agreement (as hereinafter defined), MPP has been granted by PF PRISM Holdings B.V., a private limited company (besloten vennootschap) having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“Pfizer”), the right to sublicense certain Patents (as hereinafter defined) and Licensed Know-How (as hereinafter defined) regarding (a) the Compound (as hereinafter defined) used in Product (as hereinafter defined) and Licensed Product (as hereinafter defined), (b) the Product and (c) the Licensed Product, in furtherance of its policy of improving access to COVID-19 medicines in the Territory (as hereinafter defined);
License AgreementLicense Agreement • March 2nd, 2022 • New York
Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and MSN LABORATORIES PVT LTD (MSN) a company registered under the laws of INDIA , and having as principal place of business at C-24, Sanath Nagar, Industrial Estate, Hyd-500018 (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • February 23rd, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Remington Pharmaceutical Industries (Pvt.) Ltd. a company registered under the laws of
LICENSE AGREEMENTLicense Agreement • February 22nd, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 22/02/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
License AgreementLicense Agreement • February 21st, 2022 • New York
(the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Sun Pharmaceutical Industries Ltd., a company registered under the Companies Act, 1956, (CIN : L24230GJ1993PLC019050) with its registered office at SPARC, Tandalja, Baroda, Gujarat, India, PIN - 390 012, and its corporate office at Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063, India (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • February 15th, 2022 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of22/02/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Arene Life Sciences Private Limited a company registered under the laws of India, and having as principal place of business at S.R.CHAMBERS, # 3-58, Ramachandrapuram, Sangareddy Dist, PIN code: 502 032, Telangana, India (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • November 15th, 2021 • New York
PF PRISM HOLDINGS B.V., a private limited company (besloten vennootschap) registered under the laws of the Netherlands and having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“Pfizer”);
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 22/04/2022_ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
R E C I T A L SLicense Agreement • November 11th, 2021 • New York
WHEREAS, in accordance with Pfizer-MPP Agreement (as hereinafter defined), MPP has been granted by PF PRISM Holdings B.V., a private limited company (besloten vennootschap) having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“Pfizer”), the right to sublicense certain Patents (as hereinafter defined) and Licensed Know-How (as hereinafter defined) regarding (a) the Compound (as hereinafter defined) used in Product (as hereinafter defined) and Licensed Product (as hereinafter defined), (b) the Product and (c) the Licensed Product, in furtherance of its policy of improving access to COVID-19 medicines in the Territory (as hereinafter defined);
License AgreementLicense Agreement • November 11th, 2021 • New York
WHEREAS, in accordance with Pfizer-MPP Agreement (as hereinafter defined), MPP has been granted by PF PRISM Holdings B.V., a private limited company (besloten vennootschap) having offices at Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands (“Pfizer”), the right to sublicense certain Patents (as hereinafter defined) and Licensed Know-How (as hereinafter defined) regarding (a) the Compound (as hereinafter defined) used in Product (as hereinafter defined) and Licensed Product (as hereinafter defined), (b) the Product and (c) the Licensed Product, in furtherance of its policy of improving access to COVID-19 medicines in the Territory (as hereinafter defined);
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 22/04/2022_ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Chongqing Carelife Pharmaceutical Co., Ltd. a company registered under the laws of
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 22/04/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and TRIDEM PHARMA S.A.S a company registered under the laws of France and having as principal place of business at 500 rue de l’Hers, 31750 Escalquens, France (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • November 11th, 2021 • New York
Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Apeloa Pharmaceutical Co., Ltd. a company registered under the laws of People's Republic of China , and having as principal place of business at 399 Jiangnan Road, Hengdian, Zhejiang, China (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of22/04/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
License AgreementLicense Agreement • November 11th, 2021 • New York
Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), andLab.Magnachem Intl.SRL.a company registered under the laws of
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 24/02/2022_ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
License AgreementLicense Agreement • November 11th, 2021 • New York
Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 28/02/2022_ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Amneal Pharmaceuticals LLC, a company registered under the laws of Delaware, and having a principal place of business at 400 Crossing Boulevard, Third Floor, Bridgewater, New Jersey 08807-2863 (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of22/02/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202,
LICENSE AGREEMENTLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and a company registered under the laws of
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of03/03/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Glenmark Life Sciences Limited a company registered under the laws of India, and having as principal place of business at 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400099, India (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • November 11th, 2021 • New York
Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and Shanghai Desano Bio-Pharmaceutical Co., Ltd. a company registered under the laws of China , and having as principal place of business at 1479 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China. (“Licensee”). Each of MPP and Licensee is referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
License AgreementLicense Agreement • November 11th, 2021 • New York
This LICENSE AGREEMENT (this “Agreement”) is made as of 2/21/2022 _ (the “Effective Date”) by and among the Medicines Patent Pool, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at rue de Varembé 7, Geneva 1202, Switzerland (“MPP”), and a company registered under the laws of
